Dana Investment Advisors Inc. Has $6.47 Million Stock Position in Humana Inc. (NYSE:HUM)

Share on StockTwits

Dana Investment Advisors Inc. decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,642 shares of the insurance provider’s stock after selling 1,555 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Humana were worth $6,474,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in HUM. BlackRock Inc. grew its position in shares of Humana by 3.5% in the 3rd quarter. BlackRock Inc. now owns 11,841,212 shares of the insurance provider’s stock valued at $4,900,962,000 after purchasing an additional 403,026 shares during the period. FMR LLC lifted its holdings in Humana by 28.6% during the 2nd quarter. FMR LLC now owns 7,882,151 shares of the insurance provider’s stock valued at $3,056,304,000 after purchasing an additional 1,755,293 shares during the last quarter. Jennison Associates LLC lifted its position in Humana by 72.7% during the third quarter. Jennison Associates LLC now owns 1,720,054 shares of the insurance provider’s stock worth $711,913,000 after acquiring an additional 724,288 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Humana by 13.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,446,353 shares of the insurance provider’s stock worth $560,823,000 after purchasing an additional 167,297 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Humana by 0.6% during the second quarter. Swiss National Bank now owns 610,912 shares of the insurance provider’s stock worth $236,881,000 after buying an additional 3,700 shares in the last quarter. 92.43% of the stock is owned by hedge funds and other institutional investors.

HUM traded down $0.96 during trading on Friday, hitting $406.21. 743,901 shares of the stock were exchanged, compared to its average volume of 1,034,884. The firm has a 50 day simple moving average of $426.69 and a 200 day simple moving average of $404.01. The firm has a market cap of $53.76 billion, a price-to-earnings ratio of 13.02, a P/E/G ratio of 1.96 and a beta of 0.94. Humana Inc. has a 1 year low of $208.25 and a 1 year high of $474.70. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.69 and a current ratio of 1.81.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, November 3rd. The insurance provider reported $3.08 EPS for the quarter, beating the consensus estimate of $2.81 by $0.27. The firm had revenue of $20.08 billion for the quarter, compared to analyst estimates of $18.59 billion. Humana had a return on equity of 22.74% and a net margin of 5.58%. The business’s revenue for the quarter was up 23.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.03 earnings per share. As a group, equities analysts anticipate that Humana Inc. will post 18.74 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 31st will be given a dividend of $0.625 per share. This represents a $2.50 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Wednesday, December 30th. Humana’s dividend payout ratio (DPR) is 13.99%.

Several research analysts have commented on the stock. Smith Barney Citigroup boosted their price objective on shares of Humana from $469.00 to $496.00 in a research report on Wednesday, November 4th. Mizuho upped their price objective on Humana from $420.00 to $462.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Credit Suisse Group increased their price objective on Humana from $423.00 to $465.00 and gave the company an “outperform” rating in a report on Wednesday, November 4th. Sanford C. Bernstein began coverage on shares of Humana in a research report on Thursday, October 1st. They set a “market perform” rating and a $459.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Humana from $397.00 to $431.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and a consensus target price of $447.35.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: Rule of 72

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.